News
Vaxart to Present at World Vaccine Congress Washington 2024 on April 3
-
SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, will present at the World Vaccine Congress Washington 2024 in Washington, D.C. on Wednesday, April 3, 2024. The Company has appeared repeatedly at the annual event in Washington, D.C.03/27/2024
Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14
-
SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the full year ended December 31, 2023 after the market close on Thursday, March 14, 2024.03/07/2024
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions
Is Vaxart, Inc. (VXRT) a buy, sell, or hold?
Vaxart, Inc. (VXRT) can sell. Click on Rating Page for detail.
What is Vaxart, Inc.'s stock price?
The price of Vaxart, Inc. (VXRT) is 0.735 and it was updated on 2024-05-02 13:00:39.
Is Vaxart, Inc. (VXRT) overvalued or undervalued?
Currently Vaxart, Inc. (VXRT) is in undervalued.
News
| News |
|---|
 VAXART, INC. (VXRT) is a Great Momentum Stock: Should You Buy?
|
 5 Top-Ranked Stocks That Have More Than Doubled Year to Date
|
 VAXART, INC. (VXRT) Now Trades Above Golden Cross: Time to Buy?
|
 Vaxart, Inc. (VXRT) Q3 2023 Earnings Call Transcript
|
 Vaxart to Present at World Vaccine Congress Europe 2023 on October 18-19
|
Transcripts
| Transcipts Data |
|---|
 Vaxart, Inc. (VXRT) on Q3 2023 Results - Earnings Call Transcript
|
Vaxart, Inc. (VXRT) on Q2 2023 Results - Earnings Call Transcript
|
Vaxart, Inc. (VXRT) on Q1 2023 Results - Earnings Call Transcript
|
Vaxart, Inc. (VXRT) on Q4 2022 Results - Earnings Call Transcript
|
Vaxart, Inc. (VXRT) on Q3 2022 Results - Earnings Call Transcript
|
Vaxart, Inc. (VXRT) on Q2 2022 Results - Earnings Call Transcript
|
SEC Filings
Press Releases
| StockPrice Release |
|---|
Vaxart, inc. announces management change
|
Vaxart to host investor q&a webcast
|
Vaxart shareholder alert
|
Lost money in vaxart, inc.
|
Vaxart reports q2 loss per share of $0.12
|
Vaxart quarterly loss per share $0.02
|
Vaxart reports q4 revenue of $3.9 mln
|
Vaxart, inc. announces board changes
|
Vaxart reports q3 loss per share $0.32
|
Vaxart, inc. - special call
|
More Headlines
| News |
|---|
3 Biotech Blockbusters to Turn $5,000 Into $50,000
|
Bears are Losing Control Over VAXART, INC. (VXRT), Here's Why It's a 'Buy' Now
|
Vaxart, Inc. (VXRT) Q2 2023 Earnings Call Transcript
|
VAXART, INC. (VXRT) Reports Q2 Loss, Tops Revenue Estimates
|
Why Is Vaxart (VXRT) Stock Down 25% Today?
|
These 2 Stocks Carry a Lot of Risk, but Their Upside Is Huge
|
Vaxart to Host Webcast with Key Opinion Leaders to Discuss the Health Impact and Disease Burden for Norovirus
|
Vaxart, Inc. (VXRT) Q4 2022 Earnings Call Transcript
|
Vaxart to Host Full Year 2022 Business Update and Financial Results Conference Call on March 15
|
Best Penny Stocks To Buy? 4 To Watch Before 2023
|
Vaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2022 on November 29
|
Vaxart, Inc. (VXRT) Q3 2022 Earnings Call Transcript
|
VAXART, INC. (VXRT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
|
3 Supercharged Growth Stocks With 257% to 379% Upside, According to Wall Street
|
Vaxart to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 8
|
Vaxart to Present at World Vaccine Congress Europe 2022 on October 13
|
2 Struggling Stocks to Avoid Right Now
|
Vaxart to Host Conference Call on September 1 at 8:30 AM ET to Discuss Top-line Results from Its Phase II COVID-19 Trial
|
Vaxart, Inc. (VXRT) CEO Cezar Floroiu on Q2 2022 Results - Earnings Call Transcript
|
VAXART, INC. (VXRT) Reports Q2 Loss, Lags Revenue Estimates
|
Vaxart to Host Second Quarter 2022 Business Update and Financial Results Conference Call on August 8
|
Vaxart to Present Preclinical and Clinical Data From Its COVID-19 Oral Tablet Vaccine Program at ICMI 2022
|
Vaxart to Host Investor Q&A Webcast
|
What Could a Recession Mean for Healthcare Stocks?
|
These 3 Former High-Flying Stocks Can Soar Up to 439%, According to Wall Street
|
Can This 1 Thing Hurt Vaxart?
|
3 Stocks That Have Analysts Running for the Exit
|
Make Biotech Cash Considerations With SBIO
|
Is Vaxart the Next Moderna?
|
Is It Too Late to Buy Vaxart Stock?
|
These 19 Words From Vaxart Could Mean Trouble for Vaccine Rivals
|
Vaxart: A Speculative Biotech With Potential As Covid-19 Play And Oral Vaccine Platform
|
VAXART, INC. (VXRT) Reports Q4 Loss, Lags Revenue Estimates
|
These 2 Stocks Carry a Lot of Risk, but Their Upside Is Huge
|
Earnings Preview: VAXART, INC. (VXRT) Q4 Earnings Expected to Decline
|
Is Vaxart Stock a Buy Now?
|
All You Need to Know About VAXART, INC. (VXRT) Rating Upgrade to Buy
|
Does Vaxart's Oral COVID Vaccine Have a Chance?
|
4 Under-the-Radar Stocks With 319% to 645% Upside in 2022, According to Wall Street
|
Could Vaxart's Vaccine Pill Help to End the Pandemic?
|
Which Vaccine Stocks Will Make You a Fortune in 2022?
|
Is This Vaccine Stock a Buy?
|
Vaxart: Oral Covid-19 Vaccine Is Interesting, But Questions Linger
|
Vaxart Deserves More Respect on Wall Street for Its Promising Covid-19 Vaccine
|
2 Top Healthcare Stocks Ready for a Bull Run in 2022
|
Vaxart Stock Crosses 2 Key Levels Friday: What's Next?
|
4 Growth Stocks With 119% to 189% Upside in 2022, According to Wall Street
|
Vaxart: Investment Case For An Oral COVID Vaccine Not So Hard To Swallow
|
Why Shares of Pfizer, Ocugen, and Vaxart Are Losing Ground Today
|
VXRT Stock: Other Vaccine Stocks Are Gaining But Jim Cramer Just Sent Vaxart Down
|
Why Vaxart Stock Is About Ready To See A Breakout
|
3 Vaccine Latecomers That Could Double Your Money
|
Vaxart Stock Is Being Squeezed At The End Of A Pattern
|
Vaxart: Differentiated Covid Oral Route Remains Viable
|
Vaxart to Participate at Upcoming Conferences
|
VAXART, INC. (VXRT) Reports Q3 Loss, Lags Revenue Estimates
|
Don't Write Off Vaxart, As Its Oral Vaccine Still Has a Chance
|
Can This COVID Vaccine Stock Help Make You Rich?
|
Why Ocugen Stock Is Rallying While Moderna, Novavax, Vaxart Can't Catch Up
|
Vaxart May Be a COVID Vaccine Game Changer -- but Is It Too Late?
|
VXRT Stock: Why It Saw An Increase This Week
|
Why Vaxart Shares Are Trading Higher Today
|
These 2 COVID-19 Stocks Could Boost the Market Friday
|
Why Vaxart Shares Are Surging In Thursday's After-Hours Session
|
New Duke University-led Study Shows That Vaxart's Oral COVID-19 Vaccine Candidate Reduces Airborne Transmission of SARS-CoV-2 Infection in Animal Model
|
Vaxart (VXRT) Starts Recruitment in Oral COVID-19 Vaccine Study
|
Why Vaxart Stock Tumbled in September
|
Why Investing in VXRT Stock is a Coin Flip
|
Vaxart (VXRT) Sees Hammer Chart Pattern: Time to Buy?
|
What's Going On With Vaxart's Stock?
|
Is the Options Market Predicting a Spike in Vaxart (VXRT) Stock?
|
Did You Acquire (VXRT) Before June 25, 2020? Johnson Fistel Investigates Vaxart; Should Management be Held Accountable for Investors Losses?
|
Vaccine Stocks: Why MRNA, VXRT, CVAC and NVAX Stocks Need a Band-Aid Today
|
Why Pfizer, BioNTech, Novavax, and Vaxart Stocks Are Sinking Today
|
Vaxart Traders Should Not Dismiss the Vaccine Maker's Momentum
|
Vaxart To Present at Upcoming Vaccine Conferences
|
Vaxart Announces Creation of Manufacturing and Quality Advisory Board
|
4 Small-Cap Growth Stocks Expected to Increase Sales 707% to 9,406% by 2024
|
Here's Some Good News for Vaccine Stock Investors
|
Vaxart Looks To Be On The Verge Of Breaking Out Of A Pattern
|
Vaxart Stock Is One Vaccine Also-Ran Worth Another Look
|
Vaxart to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
|
Is Vaxart Stock Really Worth a Shot?
|
Longshot Covid Play Vaxart Stock Is Too Risky at These Prices
|
7 Biotech Stocks to Buy Amid the Delta Variant's Onslaught
|
Is the Options Market Predicting a Spike in Vaxart (VXRT) Stock?
|
Vaxart Stock Probably Isn't Worth the Risk as It Pushes Higher
|
Why Shares of Vaxart Are Soaring Today
|
Volatility Plagues Wall Street During First Week of August
|
Vaxart Provides Business Update and Reports Second Quarter 2021 Financial Results
|
Why Vaxart's Stock Price Is Being Compressed In A Pennant Pattern And Looks Ready To Break Soon
|
Why Vaxart Stock Surged Today
|
Bulls Pile on VXRT After Covid-19 Vaccine Update
|
VXRT Stock: The Big FDA News Sending Vaxart Shooting Higher Today
|
Vaxart Stock Is Trading Higher As FDA Clears Mid-Stage Trial For S-Only Oral COVID-19 Vaccine Candidate
|
FDA Clears Vaxart's IND Application for S-Only Oral Tablet COVID-19 Vaccine Candidate
|
Can Last Year's Biggest Vaccine Stocks Crush the Market Again?
|
Vaxart Stock Shoots Higher After Its Oral Vaccine Boosts Immune Response In Previously Vaccinated Subject
|
VXRT Stock Increases Over 10% Pre-Market: Why It Happened
|
Vaxart Reports Boosting Immune Responses in Subjects Previously Vaccinated by a Vaxart Vaccine
|
Vaxart (VXRT) to Report Q2 Earnings: What's in the Cards?
|
Vaxart Stock Has Built-In Value Well Beyond Its Covid Pill
|
Vaxart: World's First Oral COVID Vaccine In Development
|
Vaxart Is Gaining Relevance, But Its Future Is Still Uncertain
|
Why Shares of Vaxart Jumped 31.2% in the First Half of 2021
|
Why Coronavirus Stocks Are Zooming Higher Today
|
3 Small-Cap Stocks With 158% to 329% Upside, According to Wall Street
|
Don't Count on a Covid-19 Boost for Vaxart
|
New Developments Have Made Vaxart Stock So Much More Attractive
|
Watch Out for a Selloff in Vaxart Stock
|
Vaxart (VXRT) Enters an Agreement With Altesa for Antiviral
|
Vaxart Stock Fell 3.8%: Why It Happened
|
Vaxart Inks Antiviral Asset Licensing Pact With Altesa Biosciences
|
Vaxart Stock Could Make Another Big Return in the Future
|
Will the Promise of Avoiding the Needle Pay Off for Vaxart?
|
VXRT Stock: Can Redditors Help Vaxart Power Higher?
|
Vaxart Is Still Not Worth Anywhere Near Its Present Price
|
Implied Volatility Surging for Vaxart (VXRT) Stock Options
|
Why COVID Vaccine Stocks Dynavax, Novavax, and Vaxart Are Sinking Today
|
Is It Too Late to Buy Vaxart Stock?
|
VXRT Stock Price: 21.9% Increase Explanation
|
Vaxart Has A More Sound Reason To Buy Into Its COVID-19 Vaccine Candidate
|
VXRT Stock: Why Redditors Are Betting on a Big Squeeze With Vaxart Today
|
Why Vaxart Stock Is Skyrocketing Today
|
4 Penny Stocks To Watch Hit It Big In 2021, 1 Up Over 2,200% Right Now
|
Nasdaq, Smartsheet, Twilio, Vaxart, Zoom Video and More Friday Afternoon Analyst Calls
|
Why Vaxart Shares Are Trading Higher Today
|
Bet on a No-Needle Vaccine Strategy with Vaxart
|
These Vaccine Latecomers Could Still Win Big. Here's How
|
Vaxart's Compelling Story Will Take a Long Time to Play Out
|
With Fading Covid-19 Infections, Vaxart's Relevance Is Waning
|
Speculators Should Consider Buying Vaxart Stock
|
Small-Cap & Penny Stocks To Watch In May Hitting It Big In 2021
|
Vaxart Could Still Be a Viable Covid 19 Vaccine Play
|
Ocugen or Vaxart: Which Will Take Investors Further?
|
High Cash Burn Will Push Vaxart Stock Down To $1 Per Share
|
It Won't Take Much for Vaxart Stock to Pop Once Again
|
Do Options Traders Know Something About Vaxart (VXRT) Stock We Don't?
|
Is Vaxart a Buy?
|
Vaxart's No-Shot Vaccine Is a Potential Game Changer
|
Is Vaccine Maker Vaxart Worth Holding From Here?
|
Better Vaccine Stock: Ocugen or Vaxart?
|
Vaxart's Vaccine Candidate Is a Pill, Not a Shot. Does It Matter?
|
Why Vaxart Stock Is Surging Today
|
Vaxart Stock Surges on Oral Covid-19 Vaccine Update
|
Why Vaxart Shares Popped 78% in April
|
Vaxart Stock Is Surging As Its Oral COVID-19 Vaccine Can Potentially Trigger Immunity Against Variants
|
VXRT Stock: From $8.02 To $9.48 (18.2% Increase) Pre-Market Explanation
|
New Data from Vaxart Oral COVID-19 Vaccine Phase I Study Suggests Broad Cross-Reactivity against Other Coronaviruses
|
VAXART, INC. (VXRT) Reports Q1 Loss, Misses Revenue Estimates
|
VXRT Stock: From $10.78 To Over $12.15 Pre-Market
|
Why Vaxart Stock Is Soaring Today
|
VXRT Stock: From $8.44 To $11 Explanation
|
Vaxart to Present at the World Vaccine Congress Washington 2021
|
VXRT Stock: 37.46% Increase Explanation
|
VXRT Stock: The Big Vaccine News Sending Vaxart Soaring Today
|
Vaxart Bounces At Support And Is Heading Back Up
|
5 Small-Cap Stocks With 60% to 140% Upside, According to Wall Street
|
VXRT Stock: Over 5% Increase Pre-Market Explanation
|
5 Stocks With 103% to 146% Upside, According to Wall Street
|
Should You Buy Vaxart in April?
|
These 2 Vaccine Stocks Are Bargains Right Now
|
Is the Market For a Flu Vaccine Disappearing?
|
Vaxart Stock Should Rebound After 25% Decline Over The Last Month
|
Vaxart or Inovio: Which Is More Likely to Double Your Money?
|
Vaxart Stock Trades Higher On Increased Volume: A Technical Analysis
|
Should You Buy These Vaccine Stocks After the Sell-Off?
|
Could Vaxart Be a Warren Buffett Stock?
|
Where Will Vaxart Be in 1 Year?
|
Should You Buy Vaxart Stock in March?
|
Vaxart to Present at the H.C. Wainwright Global Life Sciences Conference
|
Vaxart Stock Remains a Buy as Unique Covid-19 Vaccine Is Developed
|
VAXART, INC. (VXRT) Moves 5.6% Higher: Will This Strength Last?
|
Is Vaxart Stock Set To Decline Further?
|
Could Vaxart Be a Millionaire-Maker Stock?
|
Vaxart to Provide 2021 Business Outlook on Tuesday, March 2, 2021
|
How Risky Is Vaxart?
|
VAXART, INC. (VXRT) Stock Sinks As Market Gains: What You Should Know
|
VAXART, INC. (VXRT) Dips More Than Broader Markets: What You Should Know
|
Hedge Fund Diaries: Who Was Buying Your Stocks?
|
Vaxart (VXRT) to Report Q4 Earnings: What's in the Cards?
|
Better Coronavirus Stock: Inovio Pharmaceuticals vs. Vaxart
|
What Is Vaxart Worth Now?
|
Does Vaxart Still Have a Future?
|
Short-Sellers Just Won Their Bet on This Vaccine Stock
|
Why Vaxart Soared 109.8% In January
|
Is There Any Hope for Vaxart Stock?
|
Vaxart: Stock Drop Following Phase 1 Data For Oral COVID-19 Vaccine Is A Buying Opportunity
|
Vaxart Disappoints With Coronavirus Vaccine Trial Update
|
What's Next for Vaxart After Its Massive Meltdown?
|
Why Vaxart Stock Crashed Today
|
Biotech Bonanza: COVID Launches Science at Warp Speed
|
VXRT Stock Price Falls 57.78%: Why It Happened
|
VXRT Stock: What To Know As Covid-19 Play Vaxart Plummets
|
Vaxart plummets 62% after its oral COVID-19 vaccine fails to produce antibodies (VXRT)
|
Lifted by a Short Squeeze, Vaxart Stock Sinks on Lackluster Vaccine News
|
Vaxart's stock falls 42% after disclosing preliminary results from early-stage COVID-19 vaccine study
|
Vaxart says its oral Covid vaccine produced promising results in early trial
|
Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate
|
VXRT Stock Alert: 2 Things for Vaxart Investors to Know as Shares Pop Today
|
Vaxart, Macy's, Gogo: Will These Stocks See A GameStop Like Short Squeeze?
|
VXRT Stock Price Increases Over 25%: Why It Happened
|
Week 5 MDA Breakout Stocks - February 2021: Short-Term Picks To Give You An Edge
|
Biden's Latest Move Just Handed the Vaccine Market to These 2 Companies
|
Is Vaxart Stock a Buy?
|
VAXART ALERT: Bragar Eagel & Squire, P.C. is Investigating Vaxart, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
|
Glancy Prongay & Murray LLP Announces Investigation of Vaxart, Inc.
|
Is Vaxart Stock A Buy Ahead Of Phase 1 Data Readout?
|
Vaxart Announces Publication of a Peer-reviewed Journal Article Showing the Potential Clinical and Economic Value of a Norovirus Vaccine
|
Vaxart Announces Additional Preclinical COVID-19 Oral Vaccine Data and Publication
|
Is Vaxart Stock Worth The Risk?
|
3 Stocks That Could Realistically Triple Your Money in 2021
|
The 17 Stocks That Outperformed Tesla In 2020
|
Better Coronavirus Stock: Novavax or Vaxart?
|
Top Small Cap Stocks for February 2021
|
Do Options Traders Know Something About Vaxart (VXRT) Stock We Don't?
|
Why I'm Not Buying Vaxart Stock
|
2 COVID Vaccine Stocks That Could Trounce Pfizer and Moderna in 2021
|
Is Vaxart Stock a Buy?
|
3 Top Small-Cap Stocks to Buy in January
|
Up 1,530% in 2020, Is Vaxart Still a Buy?
|
Did You Acquire (VXRT) Before June 25, 2020? Johnson Fistel Investigates Vaxart; Should Management be Held Accountable for Investors Losses?
|
2 COVID Stocks That Turned $100,000 Into Well Over $1 Million in 2020
|
Why Vaxart Stock Plunged 28.5% in December
|
Vaxart: Practical COVID-19 Oral Pill For 2021
|
3 Coronavirus Stocks Poised to Soar in 2021
|
3 Healthcare Stocks That Turned $100,000 Into $1 Million in 2020
|
These Were the 3 Best Coronavirus Stocks of 2020
|
5 Biotech Stocks That Generated 1,000%+ Returns In 2020
|
6 Biotech/Drug Stocks Up Manifold in 2020 Thanks to COVID-19
|
These 5 Small-Cap Healthcare Stocks Gained the Most in 2020
|
Is There Still Room for Growth for These 2 Coronavirus Stocks?
|
4 Small COVID-19 Vaccine Makers to Look Out for in 2021
|
3 Healthcare Stocks to Sell Before 2021
|
3 COVID-19 Vaccine Stocks That Could Be the Biggest Winners in a Post-Pandemic World
|
These Were the 10 Best Healthcare Stocks of 2020
|
COVID Vaccine Stock Ideas for Different Investors
|
Up Almost 2,000% in 2020, Is Vaxart Still a Buy?
|
Did You Miss Out on a 2,000% Gain with Vaxart Stock?
|
3 Top Coronavirus Stocks to Watch in December
|
2 Ultra-Risky Coronavirus Stocks That Could Make You Filthy Rich
|
3 COVID Vaccine Stocks That Could Be Millionaire-Makers
|
4 Biotechs Likely to Gain on Coronavirus Vaccine Efforts
|
3 Stocks with Jaw-Dropping Growth Potential
|
Where Will Vaxart Be in 1 Year?
|
Vaxart Hosting Key Opinion Leader Panel Call for Investors
|
Vaxart Announces Presentations at the Jefferies Virtual London Healthcare Conference & the Piper Sandler Annual Healthcare Conference
|
Vaxart Reports Third Quarter 2020 Financial Results and Provides Business Update
|
7 Biotech Penny Stocks Worth a Gamble
|
How to Invest in the Coronavirus Vaccine Race Right Now
|
Why Inovio Pharmaceuticals, Novavax, and Vaxart Crashed in October
|
These 2 Coronavirus Vaccine Stocks Could Be Game-Changers
|
Avoid These 2 Coronavirus Innovator Stocks in November
|
Scott+Scott Attorneys at Law LLP Reminds Investors of Pending Securities Class Actions Against Vaxart, Inc. (VXRT) and October 23, 2020 Lead Plaintiff Deadline
|
VXRT INVESTOR FRAUD: Hagens Berman, National Trial Attorneys, Updates Vaxart (VXRT) Investors: Company Announces Recent Grand Jury Subpoena & SEC Investigation, Hagens Berman Filed Securities Fraud Class Action and Encourages Investors with Significant Lo
|
Vaxart (VXRT) Begins Dosing in Oral Coronavirus Vaccine Study
|
Covid Report: Moderna Gets Key Ruling In Europe; Vaxart Tablet Passes 'Hamster Challenge'
|
Covid-19 Vaccine In Pill Form? Vaxart Doses First Test Participants With Its Oral Tablet; Stock Jumps
|
Why Vaxart Stock Is Jumping Today
|
Rosen, A Global and Leading Law Firm, Reminds Vaxart, Inc. Investors of Important October 23 Deadline in Securities Class Action; Encourages Investors with Losses Exceeding $100K to Contact the Firm - VXRT
|
VAXART INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Vaxart, Inc. - VXRT
|
ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSEL, Reminds Vaxart, Inc. Investors of Important October 23 Deadline in Securities Class Action; Encourages Investors with Losses Exceeding $100K to Contact the Firm - VXRT
|
Why Shares of This Top Coronavirus Vaccine Hopeful Popped in September
|
Kindred Shares Up on Expansion of Agreement With Vaxart
|
2 Healthcare Stocks That Could Soar in 2020
|
VXRT INVESTOR FRAUD: Hagens Berman, National Trial Attorneys, Reminds Vaxart (VXRT) Investors of Securities Fraud Class Action and Encourages Investors with Significant Losses to Contact the Firm
|
Vaxart Ramps Up Coronavirus Vaccine Production
|
Centaur Biopharmaceutical Services Announces Expansion of Manufacturing Agreement with Vaxart for COVID-19 and Other Vaccine Candidates
|
VAXART, INC. CLASS ACTION ALERT: WOLF HALDENSTEIN ADLER FREEMAN & HERZ LLP REMINDS INVESTORS THAT A SECURITIES CLASS ACTION LAWSUIT HAS BEEN FILED ON BEHALF OF SHAREHOLDERS OF VAXART, INC.
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vaxart, Inc. - VXRT
|
Top Small Cap Stocks for October 2020
|
Rosen, Top Ranked Global Counsel, Reminds Vaxart, Inc. Investors of Important Deadline in Securities Class Action - VXRT
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds Vaxart (VXRT) Investors of Securities Fraud Class Action and Upcoming Deadline, Encourages Investors with Significant Losses to Contact the Firm
|
3 Small-Cap Stocks To Buy For Large Cap Potential
|
ROSEN, RECOGNIZED INVESTOR COUNSEL, Reminds Vaxart, Inc. Investors of Important October 23 Deadline in Securities Class Action - VXRT
|
VXRT SECURITIES FRAUD: Hagens Berman, National Trial Attorneys, Reminds Vaxart (VXRT) Investors of Securities Fraud Class Action and Encourages Investors with Significant Losses to Contact the Firm
|
Why Vaxart Stock Is Retreating Today
|
Rosen, Global Investor Counsel, Reminds Vaxart, Inc. Investors of Important Deadline in Securities Class Action - VXRT
|
3 Biotech Stocks That Surged Last Week
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds Vaxart (VXRT) Investors of Securities Fraud Class Action and Encourages Investors with Significant Losses to Contact the Firm, Application Deadline Approaching
|
Vaxart (VXRT) Surges: Stock Moves 8.1% Higher
|
5 Penny Stocks That Were Home Runs In 2020
|
Why Vaxart Stock Is Vaulting Higher Today
|
ROSEN, A TRUSTED AND TOP RANKED FIRM, Reminds Vaxart, Inc. Investors of Important Deadline in Securities Class Action - VXRT
|
Vaxart Gets FDA Nod for Phase I Study on Coronavirus Vaccine
|
Is Vaxart a Good Coronavirus Stock to Buy?
|
These 3 Coronavirus Stocks Could More Than Double by the End of 2020
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vaxart, Inc. -VXRT
|
Vaxart Gets FDA Sign-Off on Phase 1 Clinical Trial for Its Coronavirus Vaccine
|
VXRT Stock: Vaxart Shoots Higher on Human Trial Approval
|
Why Vaxart Stock Is Crushing It Today
|
Vaxart's stock rallies 15% after it gets clearance to begin human trials of COVID-19 vaccine candidate
|
Vaxart Announces FDA Clearance of IND Application for Oral COVID-19 Vaccine and Provides Update on COVID-19 Program
|
Better Coronavirus Stock: Altimmune or Vaxart?
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Vaxart (VXRT) Investors with Significant Losses to Contact the Firm, Securities Fraud Class Action Filed and Application Deadline Approaching
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Vaxart (VXRT) Investors with Significant Losses to Contact the Firm Now, Securities Fraud Class Action Filed and Application Deadline Approaching
|
2 Game-Changing Biotech Stocks That May Make You Rich
|
Investor Alert: Kaplan Fox Investigates Vaxart For Potential Securities Fraud
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Vaxart (VXRT) Investors with Significant Losses to Contact the Firm Now, Securities Fraud Class Action Filed and Important Deadline is Approaching
|
Why These 3 Coronavirus-Related Stocks Plummeted More Than 35% in August
|
PreMarket Prep Stock Of The Day: Vaxart
|
Vaxart’s Oral COVID-19 Vaccine Candidate Induces Potent Systemic and Mucosal Immune Responses in Preclinical Studies
|
ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Vaxart, Inc. Investors of Important Deadline in Securities Class Action – VXRT
|
How to Invest in Coronavirus Vaccine Stocks
|
Got $3,000? These 4 Emerging Coronavirus Vaccine Stocks Look Like a Bargain
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds Vaxart (VXRT) Investors of Securities Fraud Class Action, Encourages Investors with Significant Losses to Contact its Attorneys
|
Rosen, A Leading Law Firm, Announces Filing of Securities Class Action Lawsuit Against Vaxart, Inc. - VXRT
|
Vaxart, Inc. to Participate in September Virtual Investor Conferences
|
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Vaxart, Inc. (VXRT)
|
Vaxart: Too Early To Dismiss This COVID-19 Vaccine Opportunity
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds Vaxart (VXRT) Investors of Filed Securities Fraud Class Action, Encourages Investors with Significant Losses to Contact its Attorneys
|
VXRT Investor Update: Bronstein, Gewirtz & Grossman, LLC Notifies Vaxart, Inc. Investors of Class Action and Lead Plaintiff Deadline: October 23, 2020
|
These 2 Shocking Stocks Have Outperformed the S&P in 2020 -- by a Lot
|
Has The COVID-19 Vaccine Stock Bubble Burst?
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds Vaxart (VXRT) Investors: Securities Fraud Class Action Filed, Investors with Losses Encouraged to Contact its Attorneys Now
|
Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Vaxart, Inc.
|
VXRT Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Vaxart, Inc. Investors of Class Action and Lead Plaintiff Deadline: October 23, 2020
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Vaxart (VXRT) Investors: Firm Files Securities Class Action Complaint, Investors with Losses Encouraged to Contact its Attorneys Now
|
Vaxart Appoints Karen J. Wilson to its Board of Directors
|
These 5 Healthcare Stocks Are the Biggest Winners in 2020
|
Shareholder Alert: Robbins LLP Announces a Shareholder Has Sued Vaxart, Inc. (VXRT)
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds Vaxart (VXRT) Investors of Securities Class Action Complaint and Application Deadline, Encourages Investors with Losses to Contact its Attorneys Now
|
Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Vaxart, Inc. (VXRT) Investors
|
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Vaxart, Inc.
|
Vaxart Stock: Should You Buy the Dip?
|
What's the Outlook for Vaxart Stock?
|
Vaxart Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Vaxart, Inc. To Contact The Firm
|
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Vaxart, Inc. – VXRT
|
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Vaxart, Inc.
|
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Vaxart, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
|
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Vaxart, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
|
HAGENS BERMAN FILES SECURITIES CLASS ACTION Complaint Against Vaxart (VXRT) and Its Senior Executives
|
Scott+Scott Attorneys at Law LLP Announces Investigation into Vaxart, Inc. (VXRT)
|
3 Coronavirus Stocks That Could Double by the End of 2020
|
Did You Miss Out on the 4900% Gain With Vaxart Stock?
|
These 3 Surprising Stocks Have Beaten the Market in 2020 -- by a Lot
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds Vaxart (VXRT) Investors of Firm's Investigation into Possible Securities Fraud, Encourages Investors with $50K+ Losses and Persons Who May Assist to Contact Its Attorneys Now
|
Shareholder Alert: Robbins LLP Announces It Is Investigating Vaxart, Inc. (VXRT) for Misleading Shareholders
|
3 Reasons Doctors Will Prefer Vaxart's Coronavirus Vaccine, and 1 Reason They Might Not
|
Lost Money in Vaxart, Inc.
|
Why Novavax, Vaxart, Sorrento Therapeutics, and Other Coronavirus Stocks Plummeted Today
|
Why Vaxart Stock Jumped Today
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds Vaxart (VXRT) Investors of Firm's Investigation of Possible Securities Fraud, Encourages Investors with $50K+ Losses and Persons Who May Assist to Contact Its Attorneys Now
|
Vaxart Pushes Ahead With IND Filing for COVID-19 Vaccine Candidate
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Vaxart, Inc. - VXRT
|
Investor Alert: Ademi & O'Reilly, LLP Investigates Possible Securities Fraud of Vaxart, Inc.
|
Vaxart Announces IND Filed for COVID-19 Vaccine
|
Better Coronavirus Stock: iBio vs. Vaxart
|
Coronavirus Vaccine Efforts Key to Vaxart (VXRT) Q2 Earnings
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Vaxart (VXRT) Investors Who Suffered $50K+ Losses and Persons Who May Assist Firm's Investigation of Possible Securities Fraud to Contact Its Attorneys Now
|
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Vaxart, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm
|
2 Risky Coronavirus Vaccine Stocks That Could Make You Filthy Rich
|
3 Small-Cap Coronavirus Stocks That Could Skyrocket
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Vaxart (VXRT) Investors with Significant Losses and Persons Who May Assist Firm's Investigation of Possible Securities Fraud to Contact Its Attorneys Now
|
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Vaxart, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm
|
Vaxart (VXRT) to Report Q2 Earnings: What's in the Cards?
|
ROSEN, A TOP RANKED LAW FIRM, Announces Investigation of Securities Claims Against Vaxart, Inc. – VXRT
|
SHAREHOLDER ALERT: Investigation of Vaxart Announced by Holzer & Holzer, LLC
|
Vaxart Investor Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Vaxart, Inc. To Contact The Firm
|
This Coronavirus Stock Just Got More Attractive: Should You Buy?
|
COVID-19 Vaccine Push Brings Hope: Stock & ETF Beneficiaries
|
Better Coronavirus Stock: Inovio vs. Vaxart
|
Vaxart Investors With Losses Greater Than $50,000 Encouraged To Contact Kehoe Law Firm, P.C.
|
VAXART ALERT: Bragar Eagel & Squire, P.C. is Investigating Vaxart, Inc.
|
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Vaxart, Inc. (VXRT) on Behalf of Investors
|
RM LAW Announces Investigation of Vaxart, Inc.
|
Investor Alert: Kaplan Fox Investigates Potential Securities Fraud At Vaxart, Inc.
|
The Law Offices of Frank R. Cruz Announces Investigation of Vaxart, Inc.
|
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Vaxart, Inc.
|
VXRT SHAREHOLDER INVESTIGATION: Bernstein Liebhard Announces an Investigation into Vaxart, Inc., and Encourages Investors to Contact the Firm
|
3 Best-Performing Coronavirus Stocks of 2020 So Far: Are They Buys Now?
|
Why Moderna, Vaxart, Inovio, and BioNTech Stocks Dropped Today
|
Better Coronavirus Stock: Sorrento Therapeutics vs. Vaxart
|
Everything You Need to Know About Operation Warp Speed's Coronavirus Vaccine Accelerator
|
3 Small Biotechs in Focus on Promising Coronavirus Vaccine Data
|
Beware! Your Coronavirus Stock Might Be Crushed by the FDA
|
Coronavirus Vaccine Race: Novavax or Vaxart?
|
Vaxart's Soars YTD on Robust Coronavirus Vaccine Progress
|
Vaxart (VXRT) Catches Eye: Stock Jumps 7.9%
|
3 Game-Changing Coronavirus Vaccine Stocks That May Make You Rich
|
Why Vaxart Stock Is Soaring Today
|
Implied Volatility Surging for Vaxart (VXRT) Stock Options
|
Norovirus Gastroenteritis Costs an Estimated $10.6 Billion Each Year in the United States
|
These 2 Coronavirus Stocks Could Soar in the Second Half of 2020
|
Why Vaxart Stock Soared 40% Today
|
Why Vaxart's Stock Is Trading Higher Today
|
Vaxart Raises Approximately $90M in Gross Proceeds Through its At-The-Market-Facility
|
Everything You Need to Know About Vaxart and Its Potential Coronavirus Vaccine
|
Coronavirus Vaccine Race: Moderna or Vaxart?
|
Better Coronavirus Stock: Altimmune vs. Vaxart
|
Better Coronavirus Stock: VBI Vaccines or Vaxart?
|
Vaxart's Technology Could Be A COVID-19 Game Changer
|
Vaxart: A Speculative Buy For Its Oral COVID-19 Vaccine
|
Could Investing in Vaxart Make You a Millionaire?
|
Is It Too Late to Buy Vaxart Stock?
|
Vaxart's Oral Coronavirus Vaccine Candidate Gets Chosen by OWS
|
Why Vaxart Shares Are Vaulting Higher Again
|
Coronavirus vaccine: Vaccine is still 'a long way away,': Dr. Dara Kass
|
2 Biotech Stocks That Rocketed Higher Last Week
|
Better Coronavirus Stock: VBI Vaccines or Vaxart?
|
Smart Investors Might Consider Buying This Coronavirus Stock That Just Popped 96%
|
Covid Report: Tiny Biotech Stock Catapults 28% As Feds Eye Its Vaccine
|
Why Vaxart Stock Skyrocketed Today
|
Vaxart Rallies On Double Dose Of Positive Coronavirus Vaccine Developments
|
Vaxart shares skyrocket on news its COVID-19 vaccine candidate to be part of 'Operation Warp Speed'
|
Vaxart’s COVID-19 Vaccine Selected for the U.S. Government’s Operation Warp Speed
|
Why Vaxart, Inovio, and Sorrento Therapeutics Stocks Soared Today
|
Vaxart, Inc. Signs Memorandum of Understanding with Attwill Medical Solutions Sterilflow, LP
|
Vaxart, Inc. Set to Join Russell 3000® Index
|
Vaxart Gets New CEO, Focuses on Coronavirus Vaccine Program
|
Vaxart, Inc. Appoints New CEO to Accelerate Advancement of COVID-19 and Other Programs
|
Vaxart to Present at the Jefferies Virtual Healthcare Conference
|
Vaxart Announces Selection of its Oral COVID-19 Vaccine Lead Candidate
|
Vaxart Announces First Quarter 2020 Financial Results and Provides Corporate Update
|
Vaxart (VXRT) to Report Q1 Earnings: What's in the Cards?
|
Why Vaxart Stock Slumped Today
|
Why Vaxart Is Soaring Today
|
Vaxart Up on Pre-Clinical Data on Coronavirus Vaccine Candidates
|
Vaxart Announces Positive Pre-Clinical Data for its Oral COVID-19 Vaccine Program
|
Buy 5 Top Medical Stocks on Coronavirus Drug Trial Results
|
Expand Pharmacists’ Authority To Promote COVID-19 Vaccine Access
|
Top Sectors of Q1 & Their Winning Stocks
|
5 Stocks to Buy That Are Holding Strong While Everything Else Crumbles
|
Top Ranked Momentum Stocks to Buy for March 25th
|
Coronavirus Drug Development Race to Boost These 4 Stocks
|
Here're the 5 Big Winners from the Coronavirus Pandemic
|
Emergent (EBS) to Help Vaxart Develop Coronavirus Vaccine
|
Top Ranked Momentum Stocks to Buy for March 19th
|
Vaxart, Emergent Biosolutions Partner On Coronavirus Vaccine Development
|
Vaxart: Emergent to manufacture Vaxart's experimental COVID-19 vaccine
|
VAXART ANNOUNCES IT ENTERED INTO AN AGREEMENT WITH EMERGENT BIOSOLUTIONS FOR THE DEVELOPMENT AND MANUFACTURING OF ORAL CORONAVIRUS (COVID-19) VACCINE CANDIDATE
|
EMERGENT BIOSOLUTIONS SIGNS DEVELOPMENT AND MANUFACTURING AGREEMENT WITH VAXART FOR THEIR EXPERIMENTAL ORAL VACCINE CANDIDATE FOR CORONAVIRUS DISEASE
|
Top Ranked Momentum Stocks to Buy for March 17th
|
8 Biotechs With Coronavirus Vaccines In Development
|
How Close Are Biotechs To Bringing A COVID-19 Treatment To Market?
|
5 Reasons to Buy These Small-Cap Stocks Now
|
3 Correction-Defying Bets to Buy as Markets Brave Coronavirus
|
Trump Asks Pharma Firms to Step Up Coronavirus Vaccine Work
|
5 Biotechs That Escaped the Coronavirus Onslaught Last Week
|
Market in Correction: 5 Stocks Resist Virus Attack in February
|
Vaxart Announces $10.0 Million Registered Direct Offering Priced At-the-Market
|
4 Healthcare Stocks to Gain as Coronavirus Threat Looms Large
|
Vaxart, Inc. (VXRT) Shares March Higher, Can It Continue?
|
Vaxart (VXRT) to Make Vaccines to Check Coronavirus, Stock Up
|
Vaxart's stock rockets on heavy volume after initiating coronavirus vaccine development program
|
Vaxart Announces Initiation of Coronavirus Vaccine Program
|
The Wining Sector & Its Top Stocks in Virus-Infected January
|
Results from Influenza Challenge Study Published in Lancet Infectious Diseases
|
Vaxart, Inc. Announces Changes to its Board of Directors
|
Vaxart Announces Pricing of $8 Million Underwritten Public Offering
|
Endo Files BLA for CCH With the FDA for Cellulite Candidate (Revised)
|
VXRT Ratings Summary
VXRT Quant Ranking
